Browse > Article
http://dx.doi.org/10.3904/kjm.2013.84.3.446

Gefitinib Treatment for Pulmonary Sarcomatoid Carcinoma Driven by an EGFR Mutation: Two Cases  

Kim, Ji-Yeon (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine)
Lim, Yoojoo (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine)
Lee, Eunyoung (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine)
Kim, Mi So (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine)
Lee, Dae-Won (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine)
Kim, Tae Min (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine)
Lee, Se-Hoon (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine)
Publication Information
The Korean Journal of Medicine / v.84, no.3, 2013 , pp. 446-451 More about this Journal
Abstract
Sarcomatoid carcinoma of the lung is defined as a group of poorly differentiated non-small cell carcinomas that contain a component of sarcoma or a sarcoma-like element. Most sarcomatoid carcinomas are known to have a poor prognosis. We describe a 45-year-old female never smoker and 49-year-old female never smoker with sarcomatoid carcinomas of the lung that expressed a specific EGFR mutation: microdeletion of exon 19. Their cancers progressed rapidly, despite appropriate conventional chemotherapy. After they took the EGFR-targeted agent gefitinib, there was a dramatic reduction in tumor size. Sarcomatoid carcinoma of the lung is a rare cancer whose pathogenesis is not well understood. According to these cases, the EGFR mutation could be a driver mutation and the potential therapeutic target of EGFR-targeted agents for sarcomatoid carcinoma in lung cancer patients, especially never smokers.
Keywords
Spindle cell carcinoma; Lung neoplasms; EGFR genes; Gefitinib;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.   DOI   ScienceOn
2 Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3: 75ra26.
3 Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059-1068.   DOI   ScienceOn
4 Pelosi G, Sonzogni A, De Pas T, et al. Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol 2010;18:103-120.   DOI   ScienceOn
5 Ushiki A, Koizumi T, Kobayashi N, et al. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. Jpn J Clin Oncol 2009;39:267-270.   DOI   ScienceOn
6 Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.   DOI   ScienceOn
7 Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.   DOI   ScienceOn
8 Kaira K, Horie Y, Ayabe E, et al. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. J Thorac Oncol 2010;5:460-465.   DOI   ScienceOn
9 Italiano A, Cortot AB, Ilie M, et al. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer 2009;125:2479-2482.   DOI   ScienceOn
10 Lee S, Kim Y, Sun JM, et al. Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy. J Cancer Res Clin Oncol 2011;137:1203-1211.   DOI